GlassScriptPhysician profile
Megan Fontenot
NPI 1144991043
$3,861.73
in general payments reported to CMS, 2019-2025
34 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $831 · 2023: $619 · 2024: $1,158 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $466.33 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $461.34 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $343.86 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $171.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $134.81 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $110.52 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $99.72 | 2021-2023 | Onzetra Xsail, Contrave, Nexletol |
| Kowa Pharmaceuticals America, INC. | $98.84 | 2024-2025 | Zoryve, Livalo |
| Glaxosmithkline, LLC. | $89.38 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $83.99 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $74.93 | 2024-2025 | Voquezna |
| Acerus Pharmaceuticals Corporation | $72.32 | 2021-2022 | |
| Axsome Therapeutics, INC. | $70.14 | 2022-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.92 | 2023-2025 | Jardiance, Tradjenta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.17 | 2023-2025 | Otezla, Repatha, Repatha |
| Idorsia Pharmaceuticals US INC | $50.48 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $44.98 | 2023-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $43.48 | 2022 | |
| Ardelyx, INC. | $38.30 | 2024-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $37.11 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.74 | 2024-2025 | Caplyta |
| Corcept Therapeutics | $27.95 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $22.14 | 2025 | |
| Abbott Laboratories | $21.74 | 2024 | Freestyle Libre 3 |
| Bausch Health US, LLC | $21.62 | 2022 | |
| Dexcom, INC. | $17.87 | 2024 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $17.20 | 2021 | |
| Biogen, INC. | $16.23 | 2024 | Skyclarys |
| Merck Sharp & Dohme LLC | $15.57 | 2025 | Capvaxive |
| Sage Therapeutics, LLC | $14.62 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.98 | 2024 | |
| Sanofi Pasteur INC. | $13.43 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Fontenot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.